These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7107409)

  • 1. In vitro hypoxic cytotoxicity of nitroimidazoles: uptake and cell cycle phase specificity.
    Sutherland RM; Keng P; Conroy PJ; McDermott D; Bareham BJ; Passalacqua W
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):745-8. PubMed ID: 7107409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo radiosensitization by 2-nitroimidazoles more electron-affinic than misonidazole.
    Brown DM; Yu NY; Brown JM; Lee WW
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):435-8. PubMed ID: 7107364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.
    Sasai K; Shibamoto Y; Takahashi M; Zhou L; Hori H; Nagasawa H; Shibata T; Inayama S; Abe M
    Cancer Chemother Pharmacol; 1990; 26(2):112-6. PubMed ID: 2140730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytotoxicity of hypoxic cell sensitizers in multicell spheroids.
    Sutherland RM; Bareham BJ; Reich KA
    Cancer Clin Trials; 1980; 3(1):73-83. PubMed ID: 7389039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiosensitization in vitro and in vivo by 3-nitrotriazoles.
    Shibamoto Y; Sakano K; Kimura R; Nishidai T; Nishimoto S; Ono K; Kagiya T; Abe M
    Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1063-6. PubMed ID: 3744928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of hypoxic cell radiosensitization and the development of new sensitizers.
    Stratford IJ
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):391-8. PubMed ID: 7050037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemosensitization of the nitrosoureas by 2-nitroimidazoles in the subcutaneous 9L tumor model: pharmacokinetic and structure-activity considerations.
    Wong KH; Wallen CA; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1043-50. PubMed ID: 2140824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Present status of radiation sensitizers--hypoxic cell radiosensitizer].
    Murayama C; Mori T
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2135-41. PubMed ID: 2660744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The in vitro sensitivity of chronically hypoxic EMT6/SF cells to X-radiation and hypoxic cell radiosensitizers.
    Shrieve DC; Harris JW
    Int J Radiat Biol Relat Stud Phys Chem Med; 1985 Jul; 48(1):127-38. PubMed ID: 3159699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of nitroimidazole hypoxic cell radiosensitizers in a human tumor cell line high in intracellular glutathione.
    DeGraff WG; Russo A; Gamson J; Mitchell JB
    Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1021-4. PubMed ID: 2522917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G; Canal P; Mockey E; Vandevoorde E; Laurent F; Soula G
    J Pharmacol; 1983; 14(1):67-77. PubMed ID: 6834852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Recent advances in hypoxic cell radiosensitizer].
    Ono K; Takahashi M; Nishidai T; Shibamoto Y; Abe M
    Gan No Rinsho; 1983 Oct; 29(13):1608-12. PubMed ID: 6230470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radiosensitizer: hypoxic cell radiosensitizer].
    Mori T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1399-404. PubMed ID: 2525001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical trials of radiosensitizers: what should we expect?
    Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Mar; 10(3):425-9. PubMed ID: 6231272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the cytological effects of three hypoxic cell radiosensitizers.
    Spunberg JJ; Geard CR; Rutledge-Freeman MH
    Int J Radiat Oncol Biol Phys; 1982 Jul; 8(7):1207-15. PubMed ID: 6214532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of X-ray-induced potentially lethal damage (PLD) repair in aerobic plateau-phase Chinese hamster cells by misonidazole.
    Brown DM; Dionet C; Brown JM
    Radiat Res; 1984 Jan; 97(1):162-70. PubMed ID: 6229806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of cell-cycle progression by acute treatment with various degrees of hypoxia: modifications induced by low concentrations of misonidazole present during hypoxia.
    Pettersen EO; Lindmo T
    Br J Cancer; 1983 Dec; 48(6):809-17. PubMed ID: 6652020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
    Agrawal KC; Rupp WD; Rockwell S
    Radiat Res; 1986 Feb; 105(2):227-39. PubMed ID: 3754053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NLA-1: a 2-nitroimidazole radiosensitizer targeted to DNA by intercalation.
    Denny WA; Roberts PB; Anderson RF; Brown JM; Phil D; Wilson WR
    Int J Radiat Oncol Biol Phys; 1992; 22(3):553-6. PubMed ID: 1735695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.